Subscribe
cgore
26 June 2020Big PharmaRory O'Neill

LSPN Connect: MPP chief wants COVID-19 role

The executive director of the  Medicines Patent Pool (MPP) says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
LSPN Connect: micro-managing with Pendulum Therapeutics
6 August 2020   With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored.
Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Americas
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23 July 2020   Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Biotechnology
LSPN Connect: micro-managing with Pendulum Therapeutics
6 August 2020   With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored.
Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Americas
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23 July 2020   Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.

More on this story

Biotechnology
LSPN Connect: micro-managing with Pendulum Therapeutics
6 August 2020   With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored.
Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Americas
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23 July 2020   Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB